Know Labs Q3 2023 Earnings Call Non-Invasive Diagnostics

Know Labs presents Q3 FY2023 earnings results highlighting progress in non-invasive medical diagnostics using Bio-RFID technology. The company achieved significant sensor accuracy improvements in continuous glucose monitoring (MARD declining from 19.3% to 11.3%) and expanded its patent portfolio to 169 patents. Key milestones include Generation 1 device reveal, accelerated clinical testing with over 1.5 billion datapoints, and reduced monthly burn rate.